Gelato #44 is a hybrid crossed from taste-engineered parents Thin Mint Girl Scout Cookies and fruity indica Sunset Sherbet, a variant bred by Royal Queen Seeds. With a balanced, mellow high and a universally appealing flavour profile, this is a great strain for social use. San Francisco creators Cookie Fam Genetics have released multiple numbered phenotypes of Gelato - phenotype #33 has picked up the nickname Larry Bird in reference to the legendary player’s jersey number. This strain has an indica-leaning high and carries a THC composition that ranges from 20% to 25%.
Gelato’s buds tend to be small but they have the thick and dense structure characteristic of many indica varieties. This is a strain with immediate visual appeal: bright orange pistils stand out against forest green leaves that are accented by shades of deep purple. The purple hues come about when high concentrations of pigments called anthocyanins are stimulated by cold weather in the vegetative stage. Although the buds themselves are sticky, short stalks on the trichomes mean that this strain has a less frosty appearance than many others. Cured properly, flowers of Gelato have a predominant smell of pungent citrus, compliments of fruity parent strain Sunset Sherbet. Notes of yeast and dough can be detected as well.
Grinding up or breaking apart the flowers gives off a more herbal, earthy profile.
Description provided by Wikileaf.
Information provided could come from a third-party source, and may not accurately reflect characteristics of the medication we're associating it with - we primarily provide these descriptions for those interested in strain lineage and history, which could also be inaccurate. Any information which could be taken as medical advice should be strictly disregarded. Please consult your doctor regarding the suitability of medications for your condition(s).
About Khiron Life Sciences Corp
Founded in October 2019, working assiduously to provide best care possible to patients in the UK. That is why our primary goal is to facilitate access to high-quality cannabis-based pharmaceutical products.
Khiron Life Sciences UK was founded in October 2019 and has been working assiduously to provide best care possible to patients in the UK. That is why our primary goal is to facilitate access to high-quality cannabis-based pharmaceutical products.
Putting our patients first is what allowed Khiron Life Sciences to become the medical cannabis market leader in Latin America.
Our team is composed of experienced professionals from of the European medical cannabis industry. We are working closely with the London-based leading independent scientific body, Drug Science, responsible for Project Twenty21, the largest medical cannabis patient registry in Europe.
khironmed.co.uk